IMI Launches 9th Call for Proposals

The Innovative Medicines Initiative (IMI) is launching its 9th Call for proposals, with a total budget of €135 million (€63 million of which comes from the EU's Seventh Framework Programme, and €72 million of which comes from EFPIA companies' in-kind contributions).

Action on age-related conditions
The incidence of frailty, and a loss of muscle strength, rises with age. Those affected often experience tiredness, weight loss, frequent infections, falls, and confusion, as well as difficulties with mobility. Many will need assistance to carry out simple daily tasks and activities. Although frailty is widespread, it is often under-diagnosed.

The Call includes a topic that will use frailty and the associated loss of muscle mass and strength as a paradigm for the development of better treatments for other age-related conditions. Although the number of Europeans aged 65 and over is set to rise from 85 million in 2008 to 151 million in 2060, today's healthcare and associated regulatory systems are not geared towards this growing segment of the population.

This topic will help to speed up the development of new, more effective treatments for frailty and muscle loss. The project will include a large-scale clinical study to compare the effectiveness of a state-of-the-art treatment programme centred around physical activity with a healthy ageing counselling programme without regular physical activity.

IMI Executive Director Michel Goldman commented: "All too often, frailty goes undiagnosed and untreated, with serious consequences for patients' mobility and quality of life. This project demonstrates how IMI, by bringing together all stakeholders involved in health research, can make progress in areas where effective treatments are currently lacking."

Tapping into social media to monitor drug safety
Recent years have seen an explosion in the use of social media, applications ('apps') and online platforms that allow people to share news and information and connect with one another in unprecedented ways. At the same time, legislation requires the relevant authorities to monitor the safety of medicines by gathering information on adverse drug reactions (ADR) experienced by patients. Currently this takes place via official forms. Nevertheless, for a variety of reasons, many ADRs go unreported.

One of the main objectives of the proposed WEBAE ('Web Adverse Events') project is to develop tools to tap into the wealth of content that is openly available online to both detect ADRs, and provide patients with the most up-to-date drug safety information.

Tackling the challenges of antimicrobial resistance
The 9th Call also expands IMI's programme on antimicrobial resistance, 'New Drugs for Bad Bugs' (ND4BB). The focus of one of the topics is the urgent need to develop a new business model for antibiotic development that will reinvigorate investments in this vital area. The project resulting from this topic will have to tackle a contradiction at the heart of antibiotic development: on the one hand, pharmaceutical companies make money by selling large volumes of the drugs they develop. On the other hand, the use of new antibiotics should be restricted, so as to minimise the risk of bacteria developing resistance to them. As a result of this situation, sales are low and the costs of development often exceed the potential return on investment. This new project will develop concrete recommendations for new commercial models that provide industry with an incentive to invest in this area while ensuring that new antibiotics are used wisely.

In addition, IMI's 9th Call for proposals includes a topic on the clinical development of antibiotics to treat resistant Gram-negative pathogens, such as Escherichia coli. Drug resistant Gram-negative bacteria are responsible for two thirds of the 25 000 deaths resulting from antimicrobial resistance reported in Europe annually. This new topic focuses on gathering data on the best-available therapy for hospitalised patients with serious infections caused by multi drug resistant organisms. These data will help to better design clinical studies, thereby increasing the efficiency of antibiotic R&D. This will be tested with a new combination medicine targeting serious Gram-negative infections.

For further information, please visit:
http://www.imi.europa.eu/content/9th-call-2013

The deadline for submitting Expressions of Interest is 9 October 2013.

Most Popular Now

IBM Watson Health Recognizes Top-Perform…

IBM (NYSE: IBM) Watson Health® announced its 2020 Fortune/IBM Watson Health 100 Top Hospitals list and 15 Top Health Systems award winners, naming the top-performing hospitals and health systems in...

Chatbots can Ease Medical Providers' Bur…

COVID-19 has placed tremendous pressure on health care systems, not only for critical care but also from an anxious public looking for answers. Research from the Indiana University Kelley School...

Abbott Receives FDA Approval for New Hea…

Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has approved the company's next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The...

The New Tattoo: Drawing Electronics on S…

One day, people could monitor their own health conditions by simply picking up a pencil and drawing a bioelectronic device on their skin. In a new study, University of Missouri...

Towards an AI Diagnosis Like the Doctor…

Artificial intelligence (AI) is an important innovation in diagnostics, because it can quickly learn to recognize abnormalities that a doctor would also label as a disease. But the way that...

SARS-CoV-2 Antibody Test from Siemens He…

Public Health England, in partnership with the University of Oxford, recently conducted a head-to-head evaluation of four commercial immunoassay tests available in the UK and used for the detection of...

Researchers Develop Software to Find Dru…

Washington State University researchers have developed an easy-to-use software program to identify drug-resistant genes in bacteria. The program could make it easier to identify the deadly antimicrobial resistant bacteria that...

Philips Introduces First-of-a-Kind Mobil…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it introduced first-of-its-kind mobile Intensive Care Units (ICUs) in India. Designed to meet the critical-care requirements...

Proposed Framework for Integrating Chatb…

While the technology for developing artificial intelligence-powered chatbots has existed for some time, a new viewpoint piece in JAMA lays out the clinical, ethical, and legal aspects that must be...

Clinical-Grade Wearables Offer Continuou…

Although it might be tempting to rely on your fitness tracker to catch early signs of COVID-19, Northwestern University researchers caution that consumer wearables are not sophisticated enough to monitor...

World's Smallest Imaging Device has Hear…

A team of researchers led by the University of Adelaide and University of Stuttgart has used 3D micro-printing to develop the world's smallest, flexible scope for looking inside blood vessels...

Optimizing Neural Networks on a Brain-In…

Many computational properties are maximized when the dynamics of a network are at a "critical point", a state where systems can quickly change their overall characteristics in fundamental ways, transitioning...